Details of Disease

General Information of Disease (ID: DIS4RWOW)

Disease Name	Pain
Synonyms	neurologic pain syndrome; neurological pain disease
Disease Class	MG30-MG3Z: Pain
Definition	A nervous system disorder that has pain as a major feature.
Disease Hierarchy	DISCFBRD: Neurological disorder DIS4RWOW: Pain
ICD Code	ICD-11 ICD-11: MG30-MG3Z
Disease Identifiers	MONDO ID MONDO_0700057 MESH ID D010146 UMLS CUI C0423704 MedGen ID 602552 HPO ID HP:0012531 SNOMED CT ID 247384001

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)

This Disease is Treated as An Indication in 89 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Acetaminophen	DMUIE76	Approved	Small molecular drug	[1]
Alefacept	DMMYPWO	Approved	NA	[2]
Alphaprodine	DMB0T3D	Approved	Small molecular drug	[3]
Amitriptyline	DMK7F9S	Approved	Small molecular drug	[4]
Anileridine	DMBAUED	Approved	Small molecular drug	[5]
Anileridine Hydrochloride	DMC128O	Approved	Small molecular drug	[3]
Armodafinil	DMGB035	Approved	Small molecular drug	[6]
Aspirin	DM672AH	Approved	Small molecular drug	[7]
Brivaracetam	DMSEPK8	Approved	Small molecular drug	[8]
Bromfenac	DMKB79O	Approved	Small molecular drug	[9]
Bupivacaine	DM4PRFC	Approved	Small molecular drug	[10]
Buprenorphine	DMPRI8G	Approved	Small molecular drug	[11]
Butacaine	DM584TM	Approved	Small molecular drug	[3]
Butorphanol	DM5KYPJ	Approved	Small molecular drug	[12]
Caffeine	DMKBJWP	Approved	Small molecular drug	[13]
Calcitonin Human	DM0N9WA	Approved	NA	[14]
Capsaicin	DMGMF6V	Approved	Small molecular drug	[15]
Carprofen	DMHMP05	Approved	Small molecular drug	[16]
Celecoxib	DM6LOQU	Approved	Small molecular drug	[17]
Codeine	DMJX6ZG	Approved	Small molecular drug	[18]
Cyclobenzaprine	DM1YBRM	Approved	Small molecular drug	[19]
Dexibuprofen	DMFYBD0	Approved	Small molecular drug	[20]
Dextropropoxyphene	DM23HCX	Approved	Small molecular drug	[21]
Dezocine	DMJDB0Y	Approved	Small molecular drug	[22]
Diclofenac	DMPIHLS	Approved	Small molecular drug	[23]
Diflunisal	DM7EN8I	Approved	Small molecular drug	[24]
Dyclonine	DMU6OFP	Approved	Small molecular drug	[25]
Epalrestat	DM5OGK0	Approved	Small molecular drug	[26]
Eptazocine hbr	DMFGFCH	Approved	Small molecular drug	[3]
Ethyl chloride	DMPT8KQ	Approved	Small molecular drug	[3]
Etidocaine	DMXPI8O	Approved	Small molecular drug	[27]
Etodolac	DM6WJO9	Approved	Small molecular drug	[28]
Fenoprofen	DML5VQ0	Approved	Small molecular drug	[29]
Fentanyl	DM8WAHT	Approved	Small molecular drug	[30]
Fosfosal	DMDIC39	Approved	Small molecular drug	[3]
Hydrocodone	DMQ2JO5	Approved	Small molecular drug	[31]
Hydromorphone	DMHP21E	Approved	Small molecular drug	[3]
Ibuprofen	DM8VCBE	Approved	Small molecular drug	[32]
Ketobemidone	DMM3L6Z	Approved	Small molecular drug	[3]
Ketoprofen	DMRKXPT	Approved	Small molecular drug	[33]
Lenalidomide	DM6Q7U4	Approved	Small molecular drug	[34]
Levorphanol	DMGS80V	Approved	Small molecular drug	[3]
Lidocaine	DML4ZOT	Approved	Small molecular drug	[35]
Magnesium Sulfate	DMVEK07	Approved	Small molecular drug	[36]
Meclofenamic acid	DM05FXR	Approved	Small molecular drug	[37]
Mefenamic	DM8BCWO	Approved	NA	[38]
Mefenamic acid	DMK7HFI	Approved	Small molecular drug	[39]
Meperidine	DMX4GND	Approved	Small molecular drug	[3]
MEPTAZINOL	DMPSB8F	Approved	Small molecular drug	[3]
Metaxalone	DMXLZP6	Approved	Small molecular drug	[40]
Methadone	DMTW6IU	Approved	Small molecular drug	[41]
Methamphetamine	DMPM4SK	Approved	Small molecular drug	[42]
Midazolam	DMXOELT	Approved	Small molecular drug	[43]
Modafinil	DMYILBE	Approved	Small molecular drug	[44]
Morphine	DMRMS0L	Approved	Small molecular drug	[45]
Nabumetone	DMAT2XH	Approved	Small molecular drug	[46]
Nalbuphine	DMOSQGU	Approved	Small molecular drug	[47]
Naloxone	DM3FXMA	Approved	Small molecular drug	[48]
Naproxen	DMZ5RGV	Approved	Small molecular drug	[49]
Nefopam	DMYAA80	Approved	Small molecular drug	[3]
Oxycodone	DMXLKHV	Approved	Small molecular drug	[50]
Oxymorphone	DM65AGJ	Approved	Small molecular drug	[3]
Paclitaxel	DMLB81S	Approved	Small molecular drug	[51]
Pentazocine	DM1XBHS	Approved	Small molecular drug	[3]
Phenazopyridine	DM3MDOL	Approved	Small molecular drug	[52]
Piritramide	DM7EMDB	Approved	Small molecular drug	[3]
Piroxicam	DMTK234	Approved	Small molecular drug	[53]
Pregabalin	DMDVP3B	Approved	Small molecular drug	[54]
Prilocaine	DMI7DZ2	Approved	Small molecular drug	[55]
Propoxycaine	DMHM8ZK	Approved	Small molecular drug	[3]
Propoxyphene Hydrochloride	DMMSOLA	Approved	Small molecular drug	[3]
Propyphenazone	DM2MFZT	Approved	Small molecular drug	[3]
Reboxetine	DM26PRD	Approved	Small molecular drug	[56]
Rilpivirine	DMJ0QOW	Approved	Small molecular drug	[57]
Salicyclic acid	DM2F8XZ	Approved	Small molecular drug	[58]
Salicylamide	DMQXO1I	Approved	Small molecular drug	[3]
Sodium salicylate	DMA8E10	Approved	Small molecular drug	[3]
Strontium-89	DMQTQJU	Approved	Small molecular drug	[3]
Tetracaine	DM9J6C2	Approved	Small molecular drug	[3]
Thalidomide	DM70BU5	Approved	Small molecular drug	[59]
Tiaprofenic acid	DM23D7J	Approved	Small molecular drug	[60]
Tilidine	DMJW0VS	Approved	Small molecular drug	[3]
Tiropramide	DMRBN05	Approved	Small molecular drug	[3]
Tramadol	DMRQD04	Approved	Small molecular drug	[61]
Trolamine salicylate	DM96IIX	Approved	Small molecular drug	[3]
Ziconotide	DMSLJP4	Approved	Small molecular drug	[62]
Zohydro ER	DMY2ZYQ	Approved	NA	[63]
Dihydrocodeine	DMB0FWL	Phase 4	Small molecular drug	[13]
SYNVISC-ONE	DMPMVH1	Phase 4	NA	[64]
------------------------------------------------------------------------------------


⏷ Show the Full List of 89 Drug(s)

This Disease is Treated as An Indication in 112 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
BAX-111	DM4QKU4	Preregistration	NA	[65]
2PX	DMC6GCE	Phase 3	Small molecular drug	[66]
ALO-02	DMKLBHX	Phase 3	NA	[67]
AVP-786	DMV1SOR	Phase 3	NA	[68]
AZETIRELIN	DMLY9F1	Phase 3	Small molecular drug	[69]
CNTX-4975	DMB4JPG	Phase 3	NA	[70]
DCVax-Ovarian	DMBLASN	Phase 3	NA	[71]
Fasinumab	DM5PRLA	Phase 3	NA	[70]
FX-006	DMUU3KJ	Phase 3	NA	[72]
K-103-IP	DM9J0KD	Phase 3	NA	[73]
Morphine-6-glucuronide	DMPVW6H	Phase 3	Small molecular drug	[74]
Neocartilage	DMLW3ZO	Phase 3	NA	[75]
NKTR-181	DM45DS8	Phase 3	NA	[76]
OMS-302	DMX8HS4	Phase 3	NA	[77]
Remacemide	DM3YXP8	Phase 3	Small molecular drug	[78]
Tanezumab	DMJKWMA	Phase 3	Monoclonal antibody	[70]
ThermoProfen	DMPGH7N	Phase 3	NA	[79]
CR-845	DMJYTUQ	Phase 2/3	NA	[80]
PHN-131	DM1SV8I	Phase 2/3	Small molecular drug	[81]
SAR164877	DMOJLCV	Phase 2/3	NA	[82]
CAP-232	DMR6LXM	Phase 2a	Small molecular drug	[83]
842166X	DMOV0AP	Phase 2	Small molecular drug	[84]
ABT-229	DMN3S1B	Phase 2	Small molecular drug	[85]
ABT-639	DMEWQ4X	Phase 2	Small molecular drug	[86]
ADL-5747	DMMUPTN	Phase 2	Small molecular drug	[87]
AeroLEF	DMNO7BC	Phase 2	NA	[88]
Apadoline	DM1B8IT	Phase 2	Small molecular drug	[89]
ARRY-797	DMJ48AB	Phase 2	Small molecular drug	[90]
AYX-1	DM4CJNE	Phase 2	NA	[91]
Beta-caryophyllene	DM7583A	Phase 2	Small molecular drug	[92]
CIMICOXIB	DMTKSVA	Phase 2	Small molecular drug	[93]
CNV-2197944	DMLT7JV	Phase 2	NA	[94]
COL-1077	DMNC76I	Phase 2	NA	[95]
Conatumumab	DM2UOSN	Phase 2	Monoclonal antibody	[96]
CR-665	DMNC1AF	Phase 2	Small molecular drug	[97]
Crobenetine	DM85WID	Phase 2	Small molecular drug	[98]
DAPITANT	DMR5J6K	Phase 2	Small molecular drug	[99]
Enadoline	DMGFZOL	Phase 2	Small molecular drug	[100]
Fadolmidine	DM6RKG3	Phase 2	Small molecular drug	[101]
GRC-15300	DMWXJSZ	Phase 2	NA	[102]
GRC-17536	DMWPWF6	Phase 2	NA	[103]
Imisopasem manganese	DME3POC	Phase 2	Small molecular drug	[104]
KD-7040	DME1WV2	Phase 2	NA	[105]
LANEPITANT	DM1VK96	Phase 2	Small molecular drug	[106]
Lithium	DMZ3OU6	Phase 2	Small molecular drug	[107]
LTX-03	DMC75BW	Phase 2	NA	[70]
LY-2828360	DMO8IEZ	Phase 2	NA	[108]
LY293558	DM4N6EK	Phase 2	Small molecular drug	[109]
LY3857210	DMZO2V2	Phase 2	NA	[110]
MDT-2004	DMPUHNY	Phase 2	NA	[111]
MEDETOMIDINE	DMX9Y7V	Phase 2	Small molecular drug	[112]
MEDI7352	DM92SVC	Phase 2	NA	[70]
Met-enkephalin	DMSZFTP	Phase 2	Small molecular drug	[113]
Mitemcinal fumarate	DMOJ7QA	Phase 2	Small molecular drug	[114]
Neublastin	DMOZW4C	Phase 2	NA	[115]
Niravoline	DM81SDB	Phase 2	Small molecular drug	[116]
OCFENTANIL	DM8TDBY	Phase 2	Small molecular drug	[117]
OLT1177 gel	DMSBSCF	Phase 2	NA	[118]
OX-51	DMI9ETL	Phase 2	Small molecular drug	[119]
Oxytrex	DMC3PJS	Phase 2	NA	[120]
PF-4531083	DMJSLVB	Phase 2	NA	[121]
PQR309	DMMCYZ8	Phase 2	Small molecular drug	[122]
Resiniferatoxin	DMP62L5	Phase 2	Small molecular drug	[70]
RQ-00000007 (oral)	DMMYTRU	Phase 2	Small molecular drug	[123]
SAR292833	DM63QY0	Phase 2	NA	[124]
SC-75416	DM58HR7	Phase 2	NA	[125]
SKL-NP	DMRHD6B	Phase 2	NA	[126]
SoluMatrix naproxen	DMJ07XP	Phase 2	NA	[70]
TD-9855	DMQD5NA	Phase 2	NA	[127]
Tesofensine	DM1KGS7	Phase 2	Small molecular drug	[128]
TKA-731	DMT8SMO	Phase 2	NA	[129]
XEN-402	DMR69CG	Phase 2	Small molecular drug	[130]
BL-3010	DM1ZK12	Phase 1/2	NA	[131]
AXS-06	DMSMZMU	Phase 1	NA	[70]
BDD-10103	DMGAP53	Phase 1	NA	[132]
BIIB095	DMUC6EP	Phase 1	NA	[133]
BL-1021	DMAYSFK	Phase 1	Small molecular drug	[134]
BRL-52656	DM1V9YG	Phase 1	Small molecular drug	[135]
CC8464	DMILHMC	Phase 1	NA	[70]
COL-172	DMN1N0M	Phase 1	NA	[136]
Cyt-1010	DMTV09A	Phase 1	NA	[137]
DS-1971	DM7RCQV	Phase 1	NA	[138]
DWJ-208	DMQKDJZ	Phase 1	NA	[38]
GSK1482160	DMWDQOV	Phase 1	NA	[139]
HF-0299	DMDZQ23	Phase 1	NA	[140]
IPI-940	DMEIM5G	Phase 1	NA	[141]
IQB-9302	DMET0H4	Phase 1	NA	[142]
KW-5092	DMALK7F	Phase 1	Small molecular drug	[143]
LTX-04	DM3UY48	Phase 1	NA	[70]
MCP-201	DMW9YOJ	Phase 1	NA	[144]
MEDI-578	DMPW21Z	Phase 1	NA	[145]
MR-1817	DMVNLGW	Phase 1	NA	[146]
NTRX-07	DMF8AHP	Phase 1	NA	[147]
PF-01247324	DM93LMS	Phase 1	Small molecular drug	[148]
PF-05105679	DM4QPT0	Phase 1	NA	[149]
PF-05186462	DMUF6W9	Phase 1	NA	[150]
PF-05241328	DM2NTBL	Phase 1	NA	[150]
PF-06273340	DMMFQUT	Phase 1	NA	[151]
PF-3864086	DML0OCD	Phase 1	NA	[152]
PHE-377	DMUANF9	Phase 1	Small molecular drug	[153]
PPC-5650	DM2D7Z0	Phase 1	NA	[154]
PTI-202	DMNO91Q	Phase 1	NA	[155]
RG7893	DM1R4MQ	Phase 1	NA	[156]
SAR-114137	DMZ1XR5	Phase 1	NA	[157]
SAR-115740	DMD2VRY	Phase 1	NA	[158]
SCP-1	DMVB0F3	Phase 1	NA	[159]
SKF-105809	DMUN7EQ	Phase 1	Small molecular drug	[160]
SYN-1001	DMX05W8	Phase 1	NA	[161]
Tedalinab	DM58J7E	Phase 1	Small molecular drug	[162]
VX-128	DMC8J0G	Phase 1	NA	[70]
XEN-403	DMN0OGS	Phase 1	NA	[163]
PMID17935984C1	DMO1IHL	Clinical trial	Small molecular drug	[164]
------------------------------------------------------------------------------------


⏷ Show the Full List of 112 Drug(s)

This Disease is Treated as An Indication in 9 Patented Agent(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Imidazopyridazine derivative 3	DMXVOP3	Patented	Small molecular drug	[165]
Imidazopyridazine derivative 4	DMIAJMO	Patented	Small molecular drug	[165]
Imidazopyridazine derivative 5	DM9SXYH	Patented	Small molecular drug	[165]
Imidazopyridazine derivative 6	DM5F1LR	Patented	Small molecular drug	[165]
Imidazopyridazine derivative 7	DM5X160	Patented	Small molecular drug	[165]
Imidazopyridazine derivative 8	DMF7NXJ	Patented	Small molecular drug	[165]
Oxotetrahydro-2-H-furo[3.2-b]pyrrol-4(5-H)-yl derivative 1	DM1SH5R	Patented	Small molecular drug	[166]
PMID27998201-Compound-15	DMOB8LU	Patented	Small molecular drug	[166]
Pyridine and pyrimidine derivative 1	DMGEYJW	Patented	Small molecular drug	[167]
------------------------------------------------------------------------------------


⏷ Show the Full List of 9 Drug(s)

This Disease is Treated as An Indication in 97 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Metamizole	DM79GRO	Withdrawn from market	Small molecular drug	[3]
Zomepirac	DM7APNJ	Withdrawn from market	Small molecular drug	[3]
MONTIRELIN TETRAHYDRATE	DM31OGZ	Discontinued in Preregistration	Small molecular drug	[168]
BL-1832	DMLXHZR	Discontinued in Phase 3	NA	[169]
IoGen	DMVL8PB	Discontinued in Phase 3	NA	[170]
4030W92	DMQV4C3	Discontinued in Phase 2	Small molecular drug	[171]
ADL 10-0101	DMPFQLX	Discontinued in Phase 2	NA	[172]
AM336	DMF8KH7	Discontinued in Phase 2	Small molecular drug	[173]
AT1022	DMA3KXY	Discontinued in Phase 2	NA	[174]
ATRINOSITOL	DMXZGE5	Discontinued in Phase 2	Small molecular drug	[175]
BCH-2687	DM6ANFC	Discontinued in Phase 2	NA	[176]
BP-2.94	DMI3T64	Discontinued in Phase 2	Small molecular drug	[177]
BVT-115959	DM43JK0	Discontinued in Phase 2	NA	[178]
CereCRIB	DMG62H1	Discontinued in Phase 2	Small molecular drug	[179]
CGP-49823	DMBJQU6	Discontinued in Phase 2	Small molecular drug	[180]
CY-208243	DMP8TKA	Discontinued in Phase 2	Small molecular drug	[181]
DPI-3290	DMKGXT2	Discontinued in Phase 2	Small molecular drug	[182]
E-2078	DMHEW40	Discontinued in Phase 2	Small molecular drug	[183]
Esterom	DM1LFDG	Discontinued in Phase 2	NA	[184]
Ezlopitant	DMTUPZ2	Discontinued in Phase 2	Small molecular drug	[185]
Frakefamide	DMTRBU4	Discontinued in Phase 2	Small molecular drug	[176]
FS-205-397	DMJLEV7	Discontinued in Phase 2	Small molecular drug	[186]
GW-275919	DMOIL29	Discontinued in Phase 2	NA	[187]
JTC-801	DMV3UN4	Discontinued in Phase 2	Small molecular drug	[188]
JTS-653	DM35CQ4	Discontinued in Phase 2	NA	[189]
KW-5139	DMLOKXI	Discontinued in Phase 2	NA	[190]
Latranal	DMA54FH	Discontinued in Phase 2	NA	[191]
LTA	DMYEWMT	Discontinued in Phase 2	Small molecular drug	[192]
MIRFENTANIL HYDROCHLORIDE	DMT6IUR	Discontinued in Phase 2	Small molecular drug	[193]
NCX-701	DMWROJ5	Discontinued in Phase 2	Small molecular drug	[194]
Nitecapone	DMSJYEX	Discontinued in Phase 2	Small molecular drug	[195]
NP-118809	DM8A64W	Discontinued in Phase 2	Small molecular drug	[196]
Nuvanil	DMPM58S	Discontinued in Phase 2	NA	[197]
OxycoDex	DMHFOIX	Discontinued in Phase 2	NA	[198]
Pemedolac	DM6COPL	Discontinued in Phase 2	Small molecular drug	[199]
PRS-211375 iv	DMHDP9R	Discontinued in Phase 2	Small molecular drug	[200]
PTI-701	DMGO2AV	Discontinued in Phase 2	NA	[201]
R-84760	DM4O7KA	Discontinued in Phase 2	Small molecular drug	[202]
ReN-1869	DMHCBQS	Discontinued in Phase 2	NA	[203]
RQ-00317076	DM4GVZ9	Discontinued in Phase 2	NA	[204]
SAF-312	DMFSORX	Discontinued in Phase 2	NA	[205]
SCH-32615	DMAGBM2	Discontinued in Phase 2	Small molecular drug	[206]
SEGLITIDE	DMXZVPH	Discontinued in Phase 2	Small molecular drug	[207]
TC-2696	DMP1A4S	Discontinued in Phase 2	NA	[208]
TEBUFELONE	DMMUE8P	Discontinued in Phase 2	Small molecular drug	[209]
Transdur-sufentanil	DMX32RC	Discontinued in Phase 2	Small molecular drug	[210]
TREFENTANIL HYDROCHLORIDE	DME85Z9	Discontinued in Phase 2	Small molecular drug	[211]
Ultramorph	DMRDXYV	Discontinued in Phase 2	NA	[212]
ZD-4953	DM5UCHW	Discontinued in Phase 2	NA	[213]
ZD6416	DM46JIR	Discontinued in Phase 2	NA	[214]
ABT-202	DMG9Y80	Discontinued in Phase 1	Small molecular drug	[215]
ALGRX-1207	DM7GBMA	Discontinued in Phase 1	NA	[216]
AZD1704	DMVE4P3	Discontinued in Phase 1	NA	[217]
CTP-354	DMXY43L	Discontinued in Phase 1	NA	[218]
DUP 697	DMUMAHC	Discontinued in Phase 1	Small molecular drug	[219]
E-6087	DM79MI4	Discontinued in Phase 1	NA	[220]
PF-06260414	DMSE3WP	Discontinued in Phase 1	NA	[38]
PF-3557156	DMITYCN	Discontinued in Phase 1	NA	[221]
PTI-721	DM14J0E	Discontinued in Phase 1	NA	[222]
SDZ-NKT-343	DM8C3G5	Discontinued in Phase 1	Small molecular drug	[223]
ZD-6804	DM6TOGT	Discontinued in Phase 1	NA	[224]
ABS-212	DMZ52P6	Terminated	NA	[236]
ABT-702	DMYJMV9	Terminated	Small molecular drug	[237]
ACEA-2085	DMXLB02	Terminated	NA	[238]
AM-577	DMOIWFM	Terminated	NA	[239]
AM-66	DMGBT63	Terminated	NA	[240]
AMG-8562	DMXRQS6	Terminated	Small molecular drug	[241]
Anpirtoline	DM35LJC	Terminated	Small molecular drug	[242]
APF-580	DMYD04O	Terminated	NA	[243]
BL-1872	DMGDTLX	Terminated	NA	[244]
CEE-04-421	DMK7EV2	Terminated	NA	[245]
CM-2397	DMPYH3C	Terminated	NA	[246]
CP-331	DMCIXYR	Terminated	Small molecular drug	[247]
ENT-102	DMZZYRR	Terminated	NA	[248]
ENT-103	DMV5F4P	Terminated	NA	[249]
Flosulide	DM6OIJ1	Terminated	Small molecular drug	[250]
GP-683	DMPODL9	Terminated	Small molecular drug	[251]
GR-94839	DM96KF7	Terminated	Small molecular drug	[252]
HydrocoDex	DM4HA9C	Terminated	NA	[68]
JSM-10292	DMU5TGC	Terminated	Small molecular drug	[253]
LF-521	DM7ICPZ	Terminated	NA	[254]
MEN-10207	DM185DR	Terminated	NA	[255]
NMI-150	DMX6DNZ	Terminated	NA	[256]
NRP-388	DMDGQNW	Terminated	NA	[257]
NS-2979	DM19OGY	Terminated	NA	[258]
ONO-8711	DM2VRK7	Terminated	Small molecular drug	[259]
OX-23	DMESWV1	Terminated	Antibody	[260]
OX-30	DMVPG1N	Terminated	Antibody	[260]
PD-0204318	DMGKVPH	Terminated	NA	[261]
QX-314	DMAV2FM	Terminated	Small molecular drug	[262]
RP-67580	DMDLW64	Terminated	Small molecular drug	[263]
S-18616	DMQ8S4L	Terminated	NA	[264]
Sameridine	DMEN6YO	Terminated	Small molecular drug	[265]
SB-219825	DMQW6B0	Terminated	NA	[266]
SDZ-249482	DMPZLKC	Terminated	NA	[267]
SRSS-016	DMHCJG6	Terminated	NA	[268]
UCL-1390	DMD3CA5	Terminated	Small molecular drug	[269]
------------------------------------------------------------------------------------


⏷ Show the Full List of 97 Drug(s)

This Disease is Treated as An Indication in 11 Preclinical Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
KIT-302	DM59ENU	Application submitted	NA	[225]
A-366833	DML5SO1	Preclinical	Small molecular drug	[226]
A-425619	DMECV6L	Preclinical	Small molecular drug	[227]
A-841720	DMSO8IE	Preclinical	Small molecular drug	[228]
CNSB-004	DMHAI0M	Preclinical	NA	[229]
ED-1812	DMG4DHX	Preclinical	NA	[230]
FX-007	DMXE6ML	Preclinical	NA	[231]
IBU-PC	DMOWZGZ	Preclinical	NA	[232]
ICA-69673	DM1RZVI	Preclinical	NA	[233]
SD-726	DMEW5WL	Preclinical	NA	[234]
Syn-1002	DMWBV7G	Preclinical	NA	[235]
------------------------------------------------------------------------------------


⏷ Show the Full List of 11 Drug(s)

This Disease is Treated as An Indication in 124 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
424C79	DM42UD7	Investigative	NA	[38]
A-796260	DMHFPRJ	Investigative	Small molecular drug	[270]
A-803467	DMWGRL8	Investigative	Small molecular drug	[271]
A-967079	DMOY7TF	Investigative	Small molecular drug	[272]
A-993610	DME4ULA	Investigative	NA	[273]
AA-10022	DMTQDMR	Investigative	NA	[38]
ABT-116	DMJ6MUE	Investigative	NA	[274]
Ajinomoto 1	DMHMVOI	Investigative	NA	[26]
Ajinomoto 2	DMZE45V	Investigative	NA	[26]
Ajinomoto 3	DMG12AE	Investigative	NA	[26]
ALD-901	DMAYGK9	Investigative	Antibody	[275]
AMG-628	DMI39YX	Investigative	Small molecular drug	[276]
AMG-8563	DMU8M0I	Investigative	Small molecular drug	[277]
ANA-02	DMG2BT4	Investigative	NA	[38]
ANG-2010	DMYRDL9	Investigative	NA	[38]
APETX2	DM0JW2V	Investigative	NA	[278]
APN-601	DM26NPS	Investigative	NA	[38]
ARX-8203	DMGOCRC	Investigative	NA	[38]
AS-1892802	DMS86PI	Investigative	NA	[279]
ASP-1120	DMZY9JK	Investigative	NA	[38]
AZ-1297442	DMS8SNJ	Investigative	NA	[38]
AZ-599	DM1XE4F	Investigative	NA	[280]
BB-101	DMSOXOK	Investigative	NA	[38]
BBI-11008	DMMUIQ6	Investigative	NA	[281]
BCTC	DMT5AGJ	Investigative	Small molecular drug	[282]
BIA-10	DMULR8S	Investigative	NA	[38]
Bimetopyrole	DMPR14J	Investigative	NA	[283]
BLV-0704	DML3TSI	Investigative	NA	[38]
BPL-003	DM292M1	Investigative	NA	[38]
BRIFENTANIL	DM2JPX7	Investigative	Small molecular drug	[284]
Bulleyaconitine A	DMP7MRC	Investigative	Small molecular drug	[38]
BXL-1H5	DM9H7ZU	Investigative	NA	[38]
C-myb	DMA5Z2G	Investigative	NA	[285]
CGP-29030A	DMS61KA	Investigative	Small molecular drug	[286]
CR-4056	DM14QDU	Investigative	NA	[38]
CR-4892	DMXHIFZ	Investigative	NA	[287]
CRB-0022	DMPWZOK	Investigative	Antibody	[275]
CT-750	DMDD59L	Investigative	NA	[38]
DFU	DMUM84K	Investigative	Small molecular drug	[288]
ENDG-3010	DM1KPP2	Investigative	NA	[38]
ENDG-3020	DMV7KRL	Investigative	NA	[38]
Epoxyeicosatrienoic acid mimetics	DMD4ZBJ	Investigative	NA	[38]
ER-21041	DM6LD12	Investigative	NA	[38]
Euro-Celtique 1	DMO3AZ6	Investigative	NA	[26]
Euro-Celtique 2	DMJH4BF	Investigative	NA	[26]
Euro-Celtique 3	DM8VI3T	Investigative	NA	[26]
Euro-Celtique 4	DMO4CEL	Investigative	NA	[26]
HCGRP8-37	DMS8B1W	Investigative	NA	[38]
HPP-376	DMN2HJX	Investigative	NA	[38]
HYP-10	DMW9HTL	Investigative	NA	[289]
INP-01	DMVCJYA	Investigative	NA	[38]
INP-06	DMP54GZ	Investigative	NA	[38]
JWH-051	DMYX30S	Investigative	NA	[290]
K-103-PA	DMDVOH7	Investigative	NA	[38]
KIN-3031	DMHEOBY	Investigative	NA	[291]
KMJ-372	DMP1GQB	Investigative	NA	[274]
KST-5468	DMT0CR5	Investigative	NA	[289]
LASSBio-881	DMYNL40	Investigative	Small molecular drug	[274]
M-6040	DM1FO8A	Investigative	NA	[38]
Microxine	DM7Y9AD	Investigative	Small molecular drug	[292]
MK-3901	DM5EQ7F	Investigative	NA	[293]
MK-49	DMCJOR3	Investigative	NA	[38]
Molecule 21	DMA7T0N	Investigative	NA	[294]
MOR-6292	DMJCJBX	Investigative	NA	[38]
MorphPlus	DMZSDZR	Investigative	NA	[38]
MT-003	DM88VOW	Investigative	NA	[38]
NE-2	DMILP0F	Investigative	NA	[291]
Neo-1528	DMTQ635	Investigative	NA	[38]
Neorphine	DMZEKKN	Investigative	NA	[38]
Neuromed 2	DMSJ6T1	Investigative	NA	[26]
Neuromed 5	DMXKT45	Investigative	NA	[26]
NKTR-194	DMDEJT9	Investigative	NA	[38]
NM-007-LENK	DMAKKEA	Investigative	NA	[38]
NOX 2137a/b	DMAM5ZO	Investigative	Aptamer	[295]
NOX 2149	DMZVDLS	Investigative	Aptamer	[295]
NRD-135S	DMKRA2Q	Investigative	NA	[38]
NRI-1013	DMTSKVJ	Investigative	NA	[38]
NRP290	DMC9XJA	Investigative	NA	[296]
NRT-100	DM6U539	Investigative	NA	[38]
NRT-300	DM3IWP5	Investigative	NA	[291]
NVP-SAA164	DMN90R6	Investigative	Small molecular drug	[297]
OL-135	DMT1CZ0	Investigative	Small molecular drug	[298]
Ono 1	DMSWI4D	Investigative	NA	[26]
Ono 3	DMCG6H8	Investigative	NA	[26]
Oxindole 94	DMPFD6Y	Investigative	Small molecular drug	[299]
Parke-Davis 1	DMVI8R2	Investigative	NA	[26]
Parke-Davis 9	DMMQY42	Investigative	NA	[26]
PcTx1	DMZVJYL	Investigative	Small molecular drug	[300]
PD173212	DMRBKW6	Investigative	Small molecular drug	[26]
PD176078	DM6XHUZ	Investigative	Small molecular drug	[26]
PRTT-100	DMFAOJM	Investigative	NA	[38]
PRTT-300	DMNV5SS	Investigative	NA	[38]
PTI-601	DMQUSXK	Investigative	NA	[291]
R-116712	DMJ14OV	Investigative	NA	[301]
RAD-100	DMT8V94	Investigative	NA	[38]
RQ-00203066	DMAIOQB	Investigative	NA	[302]
SB 239063	DM201Q7	Investigative	Small molecular drug	[303]
SB-221420-A	DMMWCLV	Investigative	Small molecular drug	[26]
SCP-123	DM0KOLK	Investigative	NA	[38]
SOR-N43	DM6Y43Z	Investigative	NA	[38]
SR-14136	DMPN3Q0	Investigative	Small molecular drug	[304]
SUVN-F90101	DMALS4C	Investigative	NA	[38]
SYN-1003	DMJ9OLW	Investigative	NA	[38]
Syn-1020	DMYTEXB	Investigative	NA	[304]
T-109	DM4657K	Investigative	NA	[38]
TPR-100-Rx	DM7YKPC	Investigative	NA	[38]
TQ-1017	DMEF32D	Investigative	NA	[3]
TRI-002	DMMD8RM	Investigative	NA	[38]
TrkA-XTEN	DMHXODV	Investigative	NA	[38]
TTH 03-001	DM6NZFH	Investigative	NA	[305]
Valpentin	DMOS1A6	Investigative	NA	[38]
VH-0445 based conjugated therapeutics	DML6LZ9	Investigative	NA	[38]
VPX-595	DMC1EI5	Investigative	NA	[38]
VVZ-140	DMOL9M0	Investigative	NA	[38]
VVZ-172	DMVSOAS	Investigative	NA	[38]
WAY-256805	DM48MC3	Investigative	Small molecular drug	[306]
XEL-002BG	DMD9ND9	Investigative	NA	[38]
XEL-002BI	DMBVJOJ	Investigative	NA	[38]
XEL-002LG	DM8YTRT	Investigative	NA	[38]
XEL-004FP	DM0WFGX	Investigative	NA	[38]
XEN-401	DM6XGWT	Investigative	NA	[38]
XEN-907	DMZ24P1	Investigative	Small molecular drug	[307]
XEP-018	DMVTCZ1	Investigative	NA	[308]
ZFP TF	DM1AM0O	Investigative	NA	[38]
------------------------------------------------------------------------------------


⏷ Show the Full List of 124 Drug(s)

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

References

1	The Diversion of Ultram, Ultracet, and generic tramadol HCL. J Addict Dis. 2006;25(2):53-8.
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6787).
3	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4	Amitriptyline FDA Label
5	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7115).
6	Armodafinil FDA Label
7	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4139).
8	New molecular targets for antiepileptic drugs: alpha(2)delta, SV2A, and K(v)7/KCNQ/M potassium channels. Curr Neurol Neurosci Rep. 2008 Jul;8(4):345-52.
9	Bromfenac FDA Label
10	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
11	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1670).
12	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7591).
13	Caffeine FDA Label
14	A phase 3 trial of the efficacy and safety of oral recombinant calcitonin: the Oral Calcitonin in Postmenopausal Osteoporosis (ORACAL) trial. J Bone Miner Res. 2012 Aug;27(8):1821-9.
15	Capsaicin FDA Label
16	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7141).
17	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2892).
18	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1673).
19	Cyclobenzaprine FDA Label
20	Efficacy and Safety of NSAIDs in Infants: A Comprehensive Review of the Literature of the Past 20 Years. Paediatr Drugs. 2022 Nov;24(6):603-655.
21	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7593).
22	Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
23	Diclofenac FDA Label
24	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7162).
25	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7173).
26	Recent updates of N-type calcium channel blockers with therapeutic potential for neuropathic pain and stroke. Curr Top Med Chem. 2009;9(4):377-95.
27	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2621).
28	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7185).
29	Fenoprofen FDA Label
30	A Phase III study to assess the clinical utility of low-dose fentanyl transdermal system in patients with chronic nonmalignant pain. Curr Med Res Opin. 2006 Aug;22(8):1493-501.
31	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7081).
32	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2713).
33	Ketoprofen-induced cyclooxygenase inhibition in renal medulla and platelets of rats treated with caffeine. Pharmacology. 2001;63(4):234-9.
34	Lenalidomide FDA Label
35	Lidocaine FDA Label
36	Magnesium Sulfate FDA Label
37	Meclofenamic Acid Restores Gefinitib Sensitivity by Downregulating Breast Cancer Resistance Protein and Multidrug Resistance Protein 7 via FTO/m6A-Demethylation/c-Myc in Non-Small Cell Lung Cancer. Front Oncol. 2022 Apr 21;12:870636.
38	The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
39	Mefenamic acid FDA Label
40	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7609).
41	Methadone FDA Label
42	Pharmacotherapy for obesity. Drugs. 2005;65(10):1391-418.
43	Midazolam FDA Label
44	Modafinil FDA Label
45	Morphine FDA Label
46	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7245).
47	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1663).
48	Naloxone FDA Label
49	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5230).
50	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7093).
51	Paclitaxel FDA Label
52	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7616).
53	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7273).
54	Pregabalin FDA Label
55	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7276).
56	Gastrointestinal side effects associated with antidepressant treatments in patients with major depressive disorder: A systematic review and meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry. 2021 Jul 13;109:110266.
57	Structures of muO-conotoxins from Conus marmoreus. I nhibitors of tetrodotoxin (TTX)-sensitive and TTX-resistant sodium channels in mammalian senso... J Biol Chem. 2004 Jun 11;279(24):25774-82.
58	A standard database for drug repositioning. Sci Data. 2017 Mar 14;4:170029.
59	Thalidomide FDA Label
60	Drug information of Tiaprofenic acid, 2008. eduDrugs.
61	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8286).
62	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2536).
63	Clinical pipeline report, company report or official report of Zogenix.
64	ClinicalTrials.gov (NCT02389452) Study of Safety and Efficacy of 6 mL Synvisc-One (Hylan G-F 20) in Indian Patients With Symptomatic Osteoarthritis of Knee(s) After Initial and Repeat Treatment. U.S.National Institutes of Health.
65	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025487)
66	ClinicalTrials.gov (NCT00954629) A Study of the Efficacy and Safety of 2PX in Patients With Pain Due to Osteoarthritis of the Knee. U.S. National Institutes of Health.
67	Clinical pipeline report, company report or official report of Pfizer.
68	Antitussives and substance abuse. Subst Abuse Rehabil. 2013 Nov 6;4:75-82.
69	Developing a metagenomic view of xenobiotic metabolism. Pharmacol Res. 2013 March; 69(1): 21-31.
70	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
71	ClinicalTrials.gov (NCT00045968) Study of a Drug [DCVax-L] to Treat Newly Diagnosed GBM Brain Cancer. U.S. National Institutes of Health.
72	ClinicalTrials.gov (NCT02357459) Study of FX006 for the Treatment of Pain in Patients With Osteoarthritis of the Knee. U.S. National Institutes of Health.
73	ClinicalTrials.gov (NCT02089425) An Efficacy and Safety Study for the Treatment of Mild to Moderate Acute Pain Associated With Ankle Strain or Sprain.. U.S. National Institutes of Health.
74	ClinicalTrials.gov (NCT01082471) An Efficacy and Safety Study to Compare Morphine 6-glucuronide (M6G) and Morphine in Patients Suffering With Post-Operative Pain for at Least 24 Hours. U.S. National Institutes of Health.
75	ClinicalTrials.gov (NCT01400607) Neocartilage Implant to Treat Cartilage Lesions of the Knee. U.S. National Institutes of Health.
76	ClinicalTrials.gov (NCT02362672) Efficacy and Safety Study of NKTR-181 in Opioid-Naive Subjects With Low Back Pain. U.S. National Institutes of Health.
77	ClinicalTrials.gov (NCT01579565) Safety, Efficacy and Pharmacokinetics of OMS302 in Subjects Undergoing Intraocular Lens Replacement With Phacoemulsification. U.S. National Institutes of Health.
78	Block of the N-methyl-D-aspartate receptor by remacemide and its des-glycine metabolite. J Pharmacol Exp Ther. 1996 Jan;276(1):161-8.
79	ClinicalTrials.gov (NCT00488267) Efficacy of ThermoProfen in Patients With Mild to Moderate Pain Associated With Osteoarthritis of the Knee. U.S. National Institutes of Health.
80	ClinicalTrials.gov (NCT02542384) A Study Evaluating the Overall Pain Relief and Safety of Intravenous (IV) CR845 in Patients Undergoing Abdominal Surgery.
81	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029095)
82	ClinicalTrials.gov (NCT02447276) Study of REGN475 in Patients With Pain Due to Osteoarthritis of the Knee or Hip. U.S. National Institutes of Health.
83	ClinicalTrials.gov (NCT00735332) Efficacy Study of TLN-232 in Patients With Recurring Metastatic Melanoma. U.S. National Institutes of Health.
84	ClinicalTrials.gov (NCT00444769) Dental Pain 3rd Molar Tooth Extraction GW842166. U.S. National Institutes of Health.
85	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1444).
86	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7721).
87	ClinicalTrials.gov (NCT01058642) Study to Assess the Efficacy, Safety, and Tolerability of ADL5747 in Patients With Postherpetic Neuralgia. U.S. National Institutes of Health.
88	ClinicalTrials.gov (NCT00791804) Phase II Study of Inhaled AeroLEF for Analgesia After ACL Knee Surgery. U.S. National Institutes of Health.
89	Novel developments with selective, non-peptidic kappa-opioid receptor agonists. Expert Opin Investig Drugs. 1997 Oct;6(10):1351-68.
90	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019505)
91	ClinicalTrials.gov (NCT02081703) Study to Evaluate Safety/Efficacy of a Single Pre-Op Dose of AYX1 Injection to Treat Pain After Knee Replacement Surgery. U.S. National Institutes of Health.
92	ClinicalTrials.gov (NCT04794205) Acute Changes In Thermal Pain Response Following Single Oral Dose of Beta-Cary (BCP-Pain). U.S. National Institutes of Health.
93	ClinicalTrials.gov (NCT00510822) Cimicoxib for the Treatment of Major Depression (SECIM). U.S. National Institutes of Health.
94	ClinicalTrials.gov (NCT01848730) Efficacy and Safety of CNV2197944 Versus Placebo in Patients With Post-herpetic Neuralgia. U.S. National Institutes of Health.
95	ClinicalTrials.gov (NCT02465320) COL-1077 (Lidocaine Bioadhesive Gel, 10%) in Women Undergoing Transvaginal Pipelle-Directed Endometrial Biopsy.
96	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026807)
97	Effect of a kappa-opioid agonist, i.v. JNJ-38488502, on sensation of colonic distensions in healthy male volunteers. Neurogastroenterol Motil. 2009 Mar;21(3):281-90.
98	ClinicalTrials.gov (NCT02251197) Safety and Tolerability of BIII 890 in Patients With Acute Ischemic Stroke. U.S. National Institutes of Health.
99	Dapitant. RPR 100893. Drugs R D. 1999 Dec;2(6):383-4.
100	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1646).
101	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013220)
102	ClinicalTrials.gov (NCT01463397) Efficacy and Safety of SAR292833 Administration for 4 Weeks in Patients With Chronic Peripheral Neuropathic Pain. U.S. National Institutes of Health.
103	ClinicalTrials.gov (NCT01556152) A Clinical Trial to Study the Effects of GRC 17536 in Patients With Painful Diabetic Neuropathy (Painful Extremities Due to Peripheral Nerve Damage in Diabetic Patients). U.S. National Institutes of Health.
104	ClinicalTrials.gov (NCT00101621) Pilot Study to Evaluate the Safety and Analgesic Activity of M40403 Co-Administered With an Opioid Agent for Cancer Pain. U.S. National Institutes of Health.
105	ClinicalTrials.gov (NCT00576108) A 2 Week Study of Topical KD7040 in the Treatment of Postherpetic Neuralgia (PHN). U.S. National Institutes of Health.
106	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3510).
107	Lithium FDA Label
108	ClinicalTrials.gov (NCT01319929) A Study of LY2828360 in Patients With Osteoarthritic Knee Pain. U.S. National Institutes of Health.
109	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4245).
110	ClinicalTrials.gov (NCT05630196) Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3857210 for the Treatment of Chronic Low Back Pain. U.S.National Institutes of Health.
111	ClinicalTrials.gov (NCT00414466) A Safety and Effectiveness Study of Intraspinal Gabapentin (MDT2004) for the Treatment of Chronic Pain. U.S. National Institutes of Health.
112	Sedative and cardiopulmonary effects of medetomidine hydrochloride and xylazine hydrochloride and their reversal with atipamezole hydrochloride in calves. Am J Vet Res. 2008 Mar;69(3):319-29.
113	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1614).
114	ClinicalTrials.gov (NCT00050882) Safety and Effectiveness of an Investigational Agent (GM-611) in Patients With Diabetic Gastroparesis. U.S. National Institutes of Health.
115	ClinicalTrials.gov (NCT01873404) BG00010 (Neublastin) Phase 2 Multiple Dose Adaptive Design in Participants With Painful Lumbar Radiculopathy. U.S. National Institutes of Health.
116	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003260)
117	A phase II clinical study of once-a-day fentanyl citrate patch in patients with cancer pain--switching from once-every-three-days fentanyl patch to once-a-day fentanyl citrate patch. Gan To Kagaku Ryoho. 2010 Sep;37(9):1747-52.
118	ClinicalTrials.gov (NCT02104050) Study of OLT1177 Gel to Treat Moderate to Severe OA Knee Pain. U.S. National Institutes of Health.
119	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800033741)
120	ClinicalTrials.gov (NCT00734461) Study to Evaluate the Subjective Effects of PTI-801 in Non-Physically Dependent Subjects With a History of Drug Abuse. U.S. National Institutes of Health.
121	ClinicalTrials.gov (NCT01512160) Efficacy Of Pf-04531083 In Treating Post-Surgical Dental Pain. U.S. National Institutes of Health.
122	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8383).
123	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5858).
124	Pharmacological profiling of the TRPV3 channel in recombinant and native assays. Br J Pharmacol. 2014 May;171(10):2631-44.
125	Chromene COX-2 Inhibitor Project. Guangzhou Institutes of Biomedicine and Health,Chinese Academy of Sciences report.
126	A Novel Carbamoyloxy Arylalkanoyl Arylpiperazine Compound (SKL-NP) Inhibits Hyperpolarization-Activated Cyclic Nucleotide-Gated (HCN) Channel Currents in Rat Dorsal Root Ganglion Neurons. Korean J Physiol Pharmacol. 2012 Aug;16(4):237-41.
127	Preclinical to clinical translation of CNS transporter occupancy of TD-9855, a novel norepinephrine and serotonin reuptake inhibitor. Int J Neuropsychopharmacol. 2014 Dec 13;18(2). pii: pyu027.
128	ClinicalTrials.gov (NCT00153010) An Evaluation of Three Doses of NS 2330 in Patients With Mild to Moderate Dementia of the Alzheimer's Type. U.S. National Institutes of Health.
129	The NK1-receptor antagonist TKA731 in painful diabetic neuropathy: a randomised, controlled trial. Eur J Pain. 2006 Aug;10(6):567-71.
130	ClinicalTrials.gov (NCT01195636) A Crossover Study to Evaluate the Safety, Tolerability and Efficacy of XPF-002 in Subjects With Postherpetic Neuralgia (PHN). U.S. National Institutes of Health.
131	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800024603)
132	Clinical pipeline report, company report or official report of Birds Pharma AG.
133	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
134	ClinicalTrials.gov (NCT01121380) A Study Intended to Evaluate Safety, Tolerability and Pharmacokinetics (PK) Parameters of BL-1021. U.S. National Institutes of Health.
135	Opiate receptors within the blood-brain barrier mediate kappa agonist-induced water diuresis. J Pharmacol Exp Ther. 1993 Jul;266(1):164-71.
136	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020058)
137	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800035166)
138	ClinicalTrials.gov (NCT02564861) DS-1971a Multiple Dose Study.
139	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029786)
140	A primary adrenal steroid, 11beta-hydroxyandrostenedione, has an osteotropic effect and little androgenic activity. J Steroid Biochem Mol Biol. 2000 Nov 15;74(4):203-11.
141	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029245)
142	Stereoselective effects of the enantiomers of a new local anaesthetic, IQB-9302, on a human cardiac potassium channel (Kv1.5). Br J Pharmacol. 2001 Jan;132(2):385-92.
143	Oral administration of KW-5092, a novel gastroprokinetic agent with acetylcholinesterase inhibitory and acetylcholine release enhancing activities, causes a dose-dependent increase in the blood acetylcholine content of beagle dogs. Neurosci Lett. 1997 Mar 28;225(1):25-8.
144	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018011)
145	Clinical pipeline report, company report or official report of MedImmune (2011).
146	ClinicalTrials.gov (NCT00960180) Study Evaluating Single Ascending Doses of MR1817. U.S. National Institutes of Health.
147	ClinicalTrials.gov (NCT04375436) NTRX 07-C101: A Phase 1, Randomized, Placebo-Controlled, Modified Parallel Design Single Ascending Dose Study of NTRX 07 to Assess Safety and Tolerability and Pharmacokinetics in Adult Healthy Volunteers. U.S.National Institutes of Health.
148	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8521).
149	Inhibition of TRPM8 channels reduces pain in the cold pressor test in humans. J Pharmacol Exp Ther. 2014 Nov;351(2):259-69.
150	ClinicalTrials.gov (NCT01165736) To Calculate the Pharmacokinetics (Concentration of Compound in and Rate of Excretion From the Blood) Following a Very Low Dose of Compound Which Will Not Have Any Pharmacological Activity. U.S. National Institutes of Health.
151	ClinicalTrials.gov (NCT01601834) A First In Human Study In Healthy People To Evaluate Safety, Toleration And Time Course Of Plasma Concentration Of Single Oral Doses Of PF-06273340. U.S. National Institutes of Health.
152	ClinicalTrials.gov (NCT00747058) A Study To Investigate The Safety, Toleration And Pharmacokinetics Of Single Oral Doses Of PF-03864086 In Healthy Male Subjects. U.S. National Institutes of Health.
153	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031648)
154	ClinicalTrials.gov (NCT01449487) Investigation of Efficacy and Safety of PPC-5650 to Experimental Induced Sensation and Pain in the Rectosigmoid. U.S. National Institutes of Health.
155	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800024906)
156	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800041740)
157	From laboratory to pilot plant: the solid-state process development of a highly potent cathepsin S/K inhibitor. Eur J Pharm Biopharm. 2013 Apr;83(3):436-48.
158	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025854)
159	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800011117)
160	Analgetic activity of SK&F 105809, a dual inhibitor of arachidonic acid metabolism. Agents Actions Suppl. 1991;32:113-7.
161	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019167)
162	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800024918)
163	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032229)
164	Potent, selective spiropyrrolidine pyrimidinetrione inhibitors of MMP-13. Bioorg Med Chem Lett. 2007 Dec 1;17(23):6529-34.
165	Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).Expert Opin Ther Pat. 2016;26(4):471-83.
166	Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656.
167	Autotaxin inhibitors: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):815-829.
168	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001824)
169	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015961)
170	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800011554)
171	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006453)
172	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800011770)
173	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013107)
174	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019238)
175	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4222).
176	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009073)
177	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008192)
178	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800023039)
179	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007886)
180	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004456)
181	Decrease of behavioral and biochemical denervation supersensitivity of rat striatum by nigral transplants. Neuroscience. 1991;44(1):75-83.
182	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010668)
183	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1648).
184	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800012822)
185	Targeting pain-depressed behaviors in preclinical assays of pain and analgesia: drug effects on acetic acid-depressed locomotor activity in ICR mice. Life Sci. 2009 Aug 12;85(7-8):309-15.
186	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003851)
187	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010426)
188	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1692).
189	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800028532)
190	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002731)
191	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015196)
192	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009710)
193	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003921)
194	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014096)
195	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001267)
196	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800016715)
197	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003434)
198	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017613)
199	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002345)
200	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 746).
201	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014737)
202	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005881)
203	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014046)
204	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800034373)
205	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031053)
206	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002402)
207	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2051).
208	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021012)
209	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002346)
210	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015205)
211	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003192)
212	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013632)
213	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006843)
214	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009543)
215	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015975)
216	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800023876)
217	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800028889)
218	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800038187)
219	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000951)
220	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800016130)
221	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026842)
222	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030302)
223	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010524)
224	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009536)
225	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
226	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020139)
227	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4117).
228	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3953).
229	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029021)
230	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022365)
231	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800037108)
232	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800024759)
233	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800011004)
234	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022264)
235	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019168)
236	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5307).
237	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5131).
238	Interaction among NMDA receptor-, NMDA glycine site- and AMPA receptor antagonists in spinally mediated analgesia. Can J Anaesth. 2000 Jul;47(7):693-8.
239	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018288)
240	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019471)
241	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020509)
242	Effects of anpirtoline on regional serotonin synthesis in the rat brain: an autoradiographic study. Nucl Med Biol. 2006 Apr;33(3):325-32.
243	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026787)
244	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015962)
245	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009427)
246	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022017)
247	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001767)
248	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017903)
249	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018327)
250	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000942)
251	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006618)
252	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003733)
253	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800024715)
254	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800012973)
255	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003687)
256	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020060)
257	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800023803)
258	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013494)
259	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1920).
260	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027164)
261	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014952)
262	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2405).
263	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3522).
264	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007941)
265	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005282)
266	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008418)
267	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010408)
268	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019085)
269	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005172)
270	Indol-3-ylcycloalkyl ketones: effects of N1 substituted indole side chain variations on CB(2) cannabinoid receptor activity. J Med Chem. 2010 Jan 14;53(1):295-315.
271	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5734).
272	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6280).
273	TRPV1 receptor blockade is ineffective in different in vivo models of migraine. Cephalalgia. 2011 Jan;31(2):172-80.
274	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 507).
275	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1888).
276	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4130).
277	Altered pharmacology of native rodent spinal cord TRPV1 after phosphorylation. Br J Pharmacol. 2013 Feb;168(4):1015-29.
278	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4135).
279	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1503).
280	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 56).
281	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 317).
282	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2460).
283	Current status of COX-2 inhibitors. Mini Rev Med Chem. 2008 Jan;8(1):73-90.
284	Synthesis and pharmacological evaluation of a series of new 3-methyl-1,4-disubstituted-piperidine analgesics. J Med Chem. 1990 Oct;33(10):2876-82.
285	Cyclooxygenase-2, a colorectal cancer nonsteroidal anti-inflammatory drug target, is regulated by c-MYB. Cancer Res. 2000 Apr 1;60(7):1805-9.
286	Effects of a novel piperazine derivative (CGP 29030A) on nociceptive dorsal horn neurons in the rat. Drugs Exp Clin Res. 1992;18(11-12):447-59.
287	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 585).
288	Inhibition of cyclooxygenase-2 improves cardiac function in myocardial infarction. Biochem Biophys Res Commun. 2000 Jul 5;273(2):772-5.
289	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 536).
290	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 57).
291	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 319).
292	Inhibition of cell cycle oscillation of DNA replication by a selective inhibitor of the cdc2 kinase family, butyrolactone I, in Xenopus egg extracts. Biochem Biophys Res Commun. 1994 Jan 28;198(2):536-45.
293	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 480).
294	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 342).
295	Therapeutic applications of aptamers. Expert Opin Investig Drugs. 2008 Jan;17(1):43-60.
296	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 318).
297	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 659).
298	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5235).
299	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4307).
300	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4292).
301	Mapping of serotonin 5-HT(4) receptor mRNA and ligand binding sites in the post-mortem human brain. Synapse. 2000 Apr;36(1):35-46.
302	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 580).
303	SB-239063, a potent and selective inhibitor of p38 map kinase: preclinical pharmacokinetics and species-specific reversible isomerization. Pharm Res. 2001 Sep;18(9):1336-44.
304	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 320).
305	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 338).
306	Structure-activity relationships of the cycloalkanol ethylamine scaffold: discovery of selective norepinephrine reuptake inhibitors. J Med Chem. 2008 Jul 10;51(13):4038-49.
307	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5732).
308	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 581).
309	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800023017)